NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells

Tao, Tao; Yang, Xiaomei; Qin, Qiong; Shi, Wen; Wang, Qiqi; Yang, Ying; He, Junqi

doi:10.3390/ijms18010005

Open AccessArticle

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells

by

Tao Tao

¹,

Xiaomei Yang

^1,2,

Qiong Qin

^1,2,

Wen Shi

^1,3,

Qiqi Wang

¹,

Ying Yang

^4,* and

Junqi He

^1,2,*

¹

Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China

²

Beijing International Cooperation Base for Science and Technology on China–UK Cancer Research, Beijing 100069, China

³

Experiment Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

⁴

Core Facilities Center, Capital Medical University, Beijing 100069, China

^*

Authors to whom correspondence should be addressed.

Int. J. Mol. Sci. 2017, 18(1), 5; https://doi.org/10.3390/ijms18010005

Submission received: 19 November 2016 / Revised: 9 December 2016 / Accepted: 13 December 2016 / Published: 12 January 2017

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)

Download

Browse Figures

Versions Notes

Abstract

Cervical cancer is one of the most common female malignancies, and cisplatin-based chemotherapy is routinely utilized in locally advanced cervical cancer patients. However, resistance has been the major limitation. In this study, we found that Na⁺/H⁺ Exchanger Regulatory Factor 1 (NHERF1) was downregulated in cisplatin-resistant cells. Analysis based on a cervical cancer dataset from The Cancer Genome Atlas (TCGA) showed association of NHERF1 expression with disease-free survival of patients received cisplatin treatment. NHERF1 overexpression inhibited proliferation and enhanced apoptosis in cisplatin-resistant HeLa cells, whereas NHERF1 knockdown had inverse effects. While parental HeLa cells were more resistant to cisplatin after NHERF1 knockdown, NHERF1 overexpression in CaSki cells promoted cisplatin sensitivity. Overexpression and knockdown studies also showed that NHERF1 significantly inhibited AKT and extracellular signal–regulated kinase (ERK) signaling pathways in cisplatin-resistant cells. Taken together, our results provide the first evidence that NHERF1 can sensitize cisplatin-refractory cervical cancer cells. This study may help to increase understanding of the molecular mechanisms underlying cisplatin resistance in tumors.

Keywords: cervical cancer; NHERF1; cisplatin resistance

Graphical Abstract

Share and Cite

MDPI and ACS Style

Tao, T.; Yang, X.; Qin, Q.; Shi, W.; Wang, Q.; Yang, Y.; He, J. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells. Int. J. Mol. Sci. 2017, 18, 5. https://doi.org/10.3390/ijms18010005

AMA Style

Tao T, Yang X, Qin Q, Shi W, Wang Q, Yang Y, He J. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells. International Journal of Molecular Sciences. 2017; 18(1):5. https://doi.org/10.3390/ijms18010005

Chicago/Turabian Style

Tao, Tao, Xiaomei Yang, Qiong Qin, Wen Shi, Qiqi Wang, Ying Yang, and Junqi He. 2017. "NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells" International Journal of Molecular Sciences 18, no. 1: 5. https://doi.org/10.3390/ijms18010005

APA Style

Tao, T., Yang, X., Qin, Q., Shi, W., Wang, Q., Yang, Y., & He, J. (2017). NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells. International Journal of Molecular Sciences, 18(1), 5. https://doi.org/10.3390/ijms18010005

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI